Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease

Annals of the American Thoracic Society

Volumn 11, Issue 1, 2014, Pages 30-35

  Olivier, Kenneth N ^a   Shaw, Pamela A ^a   Glaser, Tanya S ^a   Bhattacharyya, Darshana ^a   Fleshner, Michelle ^a   Brewer, Carmen C ^b   Zalewski, Christopher K ^b   Folio, Les R ^c   Siegelman, Jenifer R ^d   Shallom, Shamira ^c   Park, In Kwon ^a   Sampaio, Elizabeth P ^a   Zelazny, Adrian M ^c   Holland, Steven M ^a   Prevots, D Rebecca ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amikacin; Antibacterial agents; Nontuberculous mycobacteria; Therapeutics

Indexed keywords

AMIKACIN;

ADULT; ARTICLE; BACTERIUM CULTURE; BRONCHIECTASIS; CILIARY DYSKINESIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONDUCTION DEAFNESS; CYSTIC FIBROSIS; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; HEMOPTYSIS; HUMAN; LOWER RESPIRATORY TRACT; LUNG DISEASE; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM INTRACELLULARE AVIUM; NEPHROTOXICITY; OTOTOXICITY; PERCEPTION DEAFNESS; REFRACTORY PULMONARY NONTUBERCULOUS MYCOBACTERIAL DISEASE; SMEAR; VERTIGO;

ADMINISTRATION, INHALATION; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; FEMALE; HUMANS; KARTAGENER SYNDROME; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84893507930     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201307-231OC     Document Type: Article

References (15)

1. Griffith DE. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010;23:185-190.
2. O'Connell ML, Birkenkamp KE, Kleiner DE, Folio LR, Holland SM, Olivier KN. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest 2012;141:1203-1209.
3. Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013;34:124-134.
4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. [Published erratum appears in Am J Respir Crit Care Med 2007;175:744-745.] (Pubitemid 46271561)
5. Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med 2008;29:569-576.
6. Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Shim TS. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011;105:781-787.
7. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Koh WJ. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.
8. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.
9. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538-1544. (Pubitemid 38738547)
10. Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F, Conlan S, McNulty S, Brown-Elliott BA, Wallace RJ Jr, et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol 2009;47:1985-1995.
11. Shallom SJ, Gardina PJ, Myers TG, Sebastian Y, Conville P, Calhoun LB, Tettelin H, Olivier KN, Uzel G, Sampaio EP, et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. J Clin Microbiol 2013;51:2943-2949.
12. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, Cambau E. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011;55:775-781.
13. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. CLSI document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. p. 14.
14. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7:2.
15. Colin AA. Eradication of Mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000;30: 267-268.